Champions Oncology, Inc. (CSBR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CSBR Revenue Growth
Revenue Breakdown (FY 2025)
CSBR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CSBR Revenue Analysis (2014–2025)
As of May 8, 2026, Champions Oncology, Inc. (CSBR) generated trailing twelve-month (TTM) revenue of $41.4 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, CSBR's 5-year compound annual growth rate (CAGR) stands at +12.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $56.9 million in 2025, representing a new all-time high.
Revenue diversification analysis shows CSBR's business is primarily driven by Pharmacology Services (85%), License and Maintenance (8%), and Product and Service, Other (6%). With over half of revenue concentrated in Pharmacology Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CASI (+21.7% YoY), TPVG, and IDXX (+13.1% YoY), CSBR has underperformed the peer group in terms of revenue growth. Compare CSBR vs CASI →
CSBR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CSBRCurrent | $41M | -100.0% | +12.1% | 8.5% | |
 CASI | $29M | +21.7% | +47.2% | -138.8% | |
 TPVG | $97M | - | - | 77.9% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% |
CSBR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $56.9M | +13.5% | $26.9M | 47.3% | $4.8M | 8.5% |
| 2024 | $50.2M | -6.9% | $20.8M | 41.4% | $-6,921,000 | -13.8% |
| 2023 | $53.9M | +9.7% | $24.3M | 45.2% | $-4,449,000 | -8.3% |
| 2022 | $49.1M | +19.7% | $25.5M | 51.9% | $607K | 1.2% |
| 2021 | $41.0M | +27.8% | $19.6M | 47.7% | $366K | 0.9% |
| 2020 | $32.1M | +18.7% | $15.1M | 47.1% | $-1,586,000 | -4.9% |
| 2019 | $27.1M | +33.7% | $12.8M | 47.3% | $270K | 1.0% |
| 2018 | $20.2M | +31.3% | $9.7M | 47.9% | $-1,354,000 | -6.7% |
| 2017 | $15.4M | +37.8% | $5.7M | 37.0% | $-6,809,000 | -44.2% |
| 2016 | $11.2M | +26.2% | $2.5M | 22.3% | $-10,316,000 | -92.3% |
See CSBR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CSBR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CSBR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCSBR — Frequently Asked Questions
Quick answers to the most common questions about buying CSBR stock.
Is CSBR's revenue growth accelerating or slowing?
CSBR revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +12.1%. TTM revenue fell to $41M. This reverses the prior growth trend.
What is CSBR's long-term revenue growth rate?
Champions Oncology, Inc.'s 5-year revenue CAGR of +12.1% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is CSBR's revenue distributed by segment?
CSBR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.